Cargando…

Caplacizumab as frontline therapy in addition to standard treatment in iTTP

Detalles Bibliográficos
Autores principales:	Cid, Joan, Lozano, Miquel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196776/ https://www.ncbi.nlm.nih.gov/pubmed/36469553 http://dx.doi.org/10.1182/bloodadvances.2022009448

Ejemplares similares

P1609: CAPLACIZUMAB THERAPY IN OLDER PATIENTS (≥60 YEARS) WITH IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP). RESULTS OF THE SPANISH TTP REGISTRY
por: Rubia, Javier DE LA, et al.
Publicado: (2023)

Management of acquired, immune thrombocytopenic purpura (iTTP): beyond the acute phase
por: Westwood, John Paul, et al.
Publicado: (2022)

Outcomes of Immune Thrombotic Thrombocytopenic Purpura (iTTP) With Upfront Cyclophosphamide vs. Rituximab
por: Abou-Ismail, Mouhamed Yazan, et al.
Publicado: (2020)

Thrombotic microangiopathy (aHUS/iTTP) reported so far in Covid-19 patients: The virus alone or an omnium gatherum of mechanisms and etiologies?
por: Mir, Tajamul H.
Publicado: (2021)

Anti-cysteine/spacer antibodies that open ADAMTS13 are a common feature in iTTP
por: De Waele, Laure, et al.
Publicado: (2021)

Assessment and Monitoring of Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): Strategies to Improve Outcomes
por: Kucukyurt, Selin, et al.
Publicado: (2020)

More on the use of frontline caplacizumab in immune-mediated thrombotic thrombocytopenic purpura
por: Picod, Adrien, et al.
Publicado: (2022)

P1608: REAL-WORLD INSIGHTS ON THE MANAGEMENT OF IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP) WITH CAPLACIZUMAB IN BELGIUM
por: Dierickx, Daan, et al.
Publicado: (2023)

Successful Treatment of Refractory Thrombotic Thrombocytopenic Purpura (TTP) With Caplacizumab: A Case Report
por: Pramanik, Debolina, et al.
Publicado: (2023)

Relapse of immune thrombotic thrombocytopenic purpura (iTTP) possibly triggered by COVID-19 vaccination and/or concurrent COVID-19 infection
por: Fang, Fei, et al.
Publicado: (2022)

Off-label caplacizumab as add-on therapy in a 9-year-old boy with refractory aTTP
por: Veltroni, Marinella, et al.
Publicado: (2021)

Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura
por: Izquierdo, Cristina Pascual, et al.
Publicado: (2022)

Caplacizumab: First Global Approval
por: Duggan, Sean
Publicado: (2018)

Caplacizumab for thrombotic thrombocytopenic purpura
Publicado: (2020)

Correction to: Caplacizumab: First Global Approval
por: Duggan, Sean
Publicado: (2018)

Caplacizumab for Acute Thrombotic Thrombocytopenic Purpura
por: Katsivalis, Katherine V., et al.
Publicado: (2021)

Caplacizumab: frequent local skin reactions
por: Kaufeld, Jessica, et al.
Publicado: (2020)

Long‐term follow‐up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post‐HERCULES study
por: Scully, Marie, et al.
Publicado: (2022)

Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura
por: Elverdi, Tugrul, et al.
Publicado: (2019)

Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis
por: Djulbegovic, Mia, et al.
Publicado: (2022)

How should caplacizumab be used for treatment of immune thrombotic thrombocytopenic purpura?
por: Zheng, Lucy, et al.
Publicado: (2023)

Prolonged Exposure to Caplacizumab as Rescue Therapy in Refractory Immune Thrombotic Thrombocytopenic Purpura
por: Rodgers, George M, et al.
Publicado: (2023)

Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura
por: Hanlon, Ashley, et al.
Publicado: (2020)

Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab
por: Sukumar, Senthil, et al.
Publicado: (2020)

From the frontlines to centre stage: resilience of frontline health workers in the context of COVID-19
por: Nanda, Priya, et al.
Publicado: (2020)

Optimizing frontline therapy in advanced urothelial cancer
por: Kwon, Whi-An, et al.
Publicado: (2020)

Immunosuppressive Therapy of Antibody-Mediated aHUS and TTP
por: Kelen, Kata, et al.
Publicado: (2023)

ADAMTS13, TTP and Beyond
por: Zheng, X Long
Publicado: (2012)

P1612: CALPROTECTIN LEVELS ARE ELEVATED IN CONGENITAL TTP AND IMMUNE TTP AT ADAMTS13 RELAPSE
por: Subhan, Maryam, et al.
Publicado: (2023)

Analisi costo-efficacia di caplacizumab nel nuovo standard of care della porpora trombotica trombocitopenica immune in Italia
por: Di Minno, Giovanni, et al.
Publicado: (2021)

The impact of excess body weight at the hospital frontline
por: Renehan, Andrew G, et al.
Publicado: (2014)

Surgery at the frontline at the time of the COVID‐19 outbreak
por: Testori, Alberto, et al.
Publicado: (2020)

Refractory Auto-Immune Thrombotic Thrombocytopenic Pupura Successfully Treated With Caplacizumab
por: Mellaza, Chloé, et al.
Publicado: (2020)

Clinical Efficacy and Safety Profile of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
por: Maqsood, Muhammad Haisum, et al.
Publicado: (2019)

Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data
por: Gavriilaki, Eleni, et al.
Publicado: (2023)

TTP: From empiricism for an enigmatic disease to targeted molecular therapies
por: Graça, Nuno A. G., et al.
Publicado: (2022)

Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab
por: Völker, Linus A., et al.
Publicado: (2020)

Hydroxychloroquine, TTP, COVID-19, and SLE
por: Sookaromdee, Pathum, et al.
Publicado: (2021)

Taking the bull by the horn: the frontline use of infliximab for the treatment of immune checkpoint inhibitor-induced enterocolitis
por: Esfahani, Khashayar
Publicado: (2018)

Treatment of Acute Kidney Injury in Hemolythic Uremic Syndrome (TTP)
por: Coric, Aida, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nsrsekenpr0t46i40jlrb16ck0